| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BRYNJELSEN SEAN | President & CEO, Director, 10%+ Owner | C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK | /s/ James R. Gruber | 05 Jun 2025 | 0001669976 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ETON | Common Stock | Sale | $1,059,224 | -60,945 | -2% | $17.38 | 3,022,568 | 03 Jun 2025 | Direct | F1, F6 |
| transaction | ETON | Common Stock | Sale | $159,079 | -8,655 | -0.29% | $18.38 | 3,013,913 | 03 Jun 2025 | Direct | F2, F6 |
| transaction | ETON | Common Stock | Sale | $7,608 | -400 | -0.01% | $19.02 | 3,013,513 | 03 Jun 2025 | Direct | F3, F6 |
| transaction | ETON | Common Stock | Sale | $1,190,000 | -70,000 | -2.3% | $17.00 | 2,943,513 | 04 Jun 2025 | Direct | F4, F6 |
| transaction | ETON | Common Stock | Sale | $1,176,700 | -70,000 | -2.4% | $16.81 | 2,873,513 | 05 Jun 2025 | Direct | F5, F6 |
| Id | Content |
|---|---|
| F1 | The shares were sold in multiple trades at prices ranging from $17.00 to $17.88. The price reported above reflects the weighted average sales price. |
| F2 | The shares were sold in multiple trades at prices ranging from $18.15 to $18.85. The price reported above reflects the weighted average sales price. |
| F3 | The shares were sold in multiple trades at a price of $19.02. |
| F4 | The shares were sold in multiple trades at prices ranging from $16.86 to $17.20. The price reported above reflects the weighted average sales price. |
| F5 | The shares were sold in multiple trades at prices ranging from $16.62 to $17.15. The price reported above reflects the weighted average sales price. |
| F6 | The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.